Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a diabetes drug help teens lose weight? new study investigates

NCT ID NCT06852391

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether adding the drug semaglutide (Wegovy®) to a behavioral lifestyle program helps teenagers with obesity lose weight and adapt their metabolism. About 74 teens aged 12-17 will be split into two groups: one gets the lifestyle program alone for 6 months, then adds semaglutide; the other gets both from the start. Researchers will measure how the body's energy use changes, aiming to find better weight management strategies.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
semaglutide (Wegovy®)
What this could lead to
If successful, this could show that combining semaglutide with a lifestyle program is more effective for weight management in teens than lifestyle changes alone.
What could go wrong
This is a small, early-phase study (74 participants) focused on metabolic changes, not long-term weight loss or safety. Semaglutide can cause side effects like nausea and vomiting, and results may not apply to all teens with obesity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 74 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

12 to 17 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Youth aged 12-17 years * Diagnosed with obesity (BMI ≥2 standard deviations above WHO Reference median) * Enrolled in Growing Health Weight Management or Next Step pediatric clinics (ie. have at least one year of the program remaining). Exclusion Criteria: * Any contraindications for MRI (i.e. claustrophobia, implanted metal, metallic injuries recent tattoo or weight \>300lb. Ineligible for imaging visit only. * Use of atypical anti-psychotics. * Use of the following medication classes: (i.e. Beta-blocker medications, Steatogenic medications, Anti-hyperglycemic medications, HIV drugs, Antidepressants, anxiolytic drugs, anti-psychotic drugs, Thyroid drugs, Antiemetic or amphetamine, dextromethorphan and metoclopramide.) * Elevated alanine aminotransferase (ALT) \> 5 x upper range of normal at screening. * Use of glucose lowering or any anti-obesity medication in the previous 3 months. * Known monogenic, syndromic or hypothalamic causes of obesity. * Diagnosis of type 1 or 2 diabetes mellitus. * Prior bariatric surgery or liver transplantation. * Alcohol intake exceeding 3 drinks per week or reported cannabis use. * Recent history of cigarette smoking (previous 3 months) - ineligible for imaging only. * History or family history of multiple endocrine neoplasia 2 or medullary thyroid cancer. * History of pancreatitis. * Presence of untreated endocrine disorder. * History of an eating disorder and / or history of suicidal ideation * History of a cardiac condition that precludes exercise testing or unable to have exercise testing done in the GHWM pediatric clinic, inability to use a cycle ergometer. Participant who does not have a peak power value obtained in the GHWM pediatric clinic Female who is pregnant, breast-feeding or intends to become pregnant. Female who refuses to use a means of contraception if sexually active. Participation in any interventional clinical study within 90 days before screening.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity (disorder) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Weight Loss

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • McMaster University

    RECRUITING

    Hamilton, Ontario, L8S 4L8, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.